PF Awareness Month emphasises the importance of early diagnosis [Yahoo! Finance]
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: Yahoo! Finance
Early detection of PF is really important, so understanding the symptoms is crucial so that patients are able to seek a diagnosis as soon as possible. Common symptoms of PF include a persistent cough that lasts more than three months, shortness of breath, ongoing fatigue, and unintended weight loss. Currently, treatment options for PF primarily aim to slow disease progression rather than reverse lung damage and scarring. The anti-fibrotic medications, pirfenidone and nintedanib, are approved therapies that target the biological processes involved in lung scarring. Additionally, oxygen therapy is needed in many PF cases, because as the disease progresses, the patient's lungs will get smaller and stiffer, and oxygen levels will begin to decrease. Currently, the only cure for PF is a lung transplant. However, the operation is complicated and comes with many risks, and some patients may not be eligible for a lung transplant. While many other treatment options are available, none stop
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
- Pliant Therapeutics: Good Data, But Will Need Watching [Seeking Alpha]Seeking Alpha
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024GlobeNewswire
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $33.00 price target on the stock.MarketBeat
PLRX
Earnings
- 11/9/23 - Beat
PLRX
Sec Filings
- 9/27/24 - Form 8-K
- 8/7/24 - Form 10-Q
- 8/7/24 - Form 8-K
- PLRX's page on the SEC website